Clinical Trial Update: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of BRD/BET inhibitors BMS-986158 and BMS-986378 in pediatric cancers has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Lymphoma
• Solid Tumor

Drugs mentioned

• BMS-986158 (BMS-986158)
• BMS-986378

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Solid Tumor, Childhood, Lymphoma | Phase 1 | Status: COMPLETED